Navigation Links
Radient Pharmaceuticals Announces FY 2011 Third Quarter Results
Date:11/14/2011

TUSTIN, Calif., Nov. 14, 2011 /PRNewswire/ -- Radient Pharmaceuticals Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced financial results for its third quarter ended September 30, 2011.

Revenues for the third quarter ended September 30, 2011 were $102,238 as compared to $34,446 for the quarter ended September 30, 2010.  For the nine months ended September 30, 2011, revenues were $257,609, as compared to $116,840 for the nine months ended September 30, 2010.  Loss from operations for the three months ended September 30, 2011 was $1,801,713, as compared to $2,338,665 for the three months ended September 30, 2010. The $536,952 (approximately 23%) decrease in our losses from operations was primarily due to an increase in sales combined with a decrease in selling, general and administrative expenses and research and development expenses.

Similarly, loss from operations for the nine months ended September 30, 2011 was $5,620,761, as compared to a loss of $6,705,359 in the nine months ended September 30, 2010.  The $1,084,598 (approximately 16%) decrease in loss from operations was primarily due to an increase in sales combined with a decrease in selling, general and administrative expenses and research and development expenses.

Net income for the three months ended September 30, 2011 was $1,947,075 or a basic and diluted income of $0.01 per common share.  Net income included a gain of $12,312,333 from the change in fair value of derivative instruments.  Net loss for the same period in 2010 was $11,946,784 or a basic and diluted loss of $0.39 per common share.

For the nine months ended September 30, 2011 the net loss was $39,417,159 or a basic and diluted loss of $0.24 per common share, as compared to a net loss of $38,420,688 or a basic and diluted loss per common shares of $1.38.  The increase in net loss is attributed to higher interest expense, legal settlement expenses, loss of guarantee and a loss on extinguishment of debt, offset by a gain on change in fair value of derivative liabilities. The complete filing is available at www.sec.gov.

"We continue to work to significantly increase revenues, subject to adequate funding for marketing efforts, with outreach to healthcare professionals and negotiations for additional distribution agreements in key international markets.  Our Onko-Sure® IVD cancer diagnostic test kit, a simple, non-invasive blood test, has shown internationally to be effective in monitoring and detecting solid cancer tumors by measuring a specific breakdown product in the blood.  Nineteen different types of cancer have been identified with the test," said Douglas MacLellan, Chairman and CEO.

The following table is intended to provide the latest information on Radient's business metrics.Radient's Business MetricsCash on hand: $103,000*

*Approximate amount as of November 11, 2011Common Shares Outstanding:  746 million*

*Approximate number as of November 11, 2011.

  5 billion shares authorized.Outstanding Warrants & Options:  110 million*

*Approximate number as of  November 11, 2011About Radient Pharmaceuticals:Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Paul Knopick
E & E Communications
949.707.5365
pknopick@eandecommunications.com


'/>"/>

SOURCE Radient Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Use of PressureWire(R) Yields a More Accurate Assessment of Translesion Pressure Gradients in Peripheral Vasculature, Two New Studies Report
2. Radient Pharmaceuticals Corporation Joins OTCQX
3. Merriman Capital Announces Sponsorship of Radient Pharmaceuticals Corporation on OTCQX
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ORLANDO, Fla. , Feb. 8, 2016 ... and marketing high performance apparel for healthcare and other ... Bold Chief Executive Officer. He replaces Dale ... and remains Chairman. Mr. Bold is also joining Vestagen,s ... in a new class of active barrier technologies that ...
(Date:2/8/2016)... Corporation ("Unilife" or "Company") (NASDAQ: UNIS ; ASX: UNS), ... announced that it will release its financial results for the ... close on February 9, 2016.  At this time, the Company ... results.    About Unilife Corporation --> ... Unilife Corporation UNIS / ASX: UNS) ...
(Date:2/8/2016)... Feb. 8, 2016  Astellas Pharma Inc. President and Chief ... of James Robinson as president, Americas Operations, for ... North and South America , effective April ... representing the commercial organization in the United States ... Masao Yoshida , who is retiring in June ...
Breaking Medicine Technology:
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. ... organizations with the tools and information to lower the costs, and increase the ... cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... , MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & ... nurses in the world with an estimated 5000 perioperative nurses in attendance ...
(Date:2/6/2016)... ... 2016 , ... With the FCPX LUT: Summer pack from Pixel ... A LUT is a Lookup Table that contains a mathematical formula for modifying an ... table. By manipulating each pixel, LUT's can change each color range differently, it gives ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research ... treatment helps to reduce the frequency and level of relapse. , ... Healthy Identity and Purpose,” will explore the critical tasks of the recovery phase ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Love is in ... in a variety of colors, assortments and packaging. This staple for Valentine’s Day is ... Kullen location. , For Valentine’s Day, not only are long-stem roses available, but ...
Breaking Medicine News(10 mins):